CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells

RT Bergstrom, DA Silverman… - … --Head and Neck …, 2004 - journals.sagepub.com
RT Bergstrom, DA Silverman, K Chambers, JA Kim
Otolaryngology--Head and Neck Surgery, 2004journals.sagepub.com
OBJECTIVE: The goal of this study was to determine whether CD40 ligation of antigen
presenting cells (APCs) enhances the anti-tumor effector function of tumor draining lymph
node (TDLN) T lymphocytes in an adoptive immunotherapy model. STUDY DESIGN: MCA
205 TDLNs were culture activated both in the presence and absence of a stimulatory anti-
CD40 monoclonal antibody (mAb) and effector cell phenotype, cytokine secretion in vitro
and therapeutic efficacy in vivo were compared. RESULTS: Anti-CD40 mAb induced …
OBJECTIVE: The goal of this study was to determine whether CD40 ligation of antigen presenting cells (APCs) enhances the anti-tumor effector function of tumor draining lymph node (TDLN) T lymphocytes in an adoptive immunotherapy model.
STUDY DESIGN: MCA 205 TDLNs were culture activated both in the presence and absence of a stimulatory anti-CD40 monoclonal antibody (mAb) and effector cell phenotype, cytokine secretion in vitro and therapeutic efficacy in vivo were compared.
RESULTS: Anti-CD40 mAb induced upregulation of APC cell surface activation markers that promoted generation of T cells that demonstrated an increase in tumor-specific IFN-gamma secretion and a statistically significant reduction in the number of pulmonary tumors (p< 0.01) after adoptive transfer.
CONCLUSION: CD40 ligation of APCs in vitro results in the generation of T cells with enhanced effector function against established pulmonary tumors in vivo.
SIGNIFICANCE: These findings have direct implications in the development of effective T cell-based immunotherapy of malignant conditions in human beings.
Sage Journals